THF-γ2-mediated reduction of pulmonary metastases and augmentation of immunocompetence in C57BL/6 mice bearing B16-melanoma

Journal of Immunotherapy

Volumn 22, Issue 2, 1999, Pages 103-113

  Ophir, Rachel ^a   Moalem, Gila ^a   Pecht, Marit ^b   Shashoua, Merav ^a   Rashid, Gloria ^a   Ben Efraim, Shlomo ^a   Trainin, Nathan ^b   Burstein, Yigal ^b   Keisari, Yona ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

B16 F10.9 melanoma; BCNU chemotherapy; Lung metastases; THF 2 immunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; HUMORAL THYMUS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; IMMUNOCOMPETENCE; LUNG METASTASIS; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; FEMALE; LUNG; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; THYMUS HORMONES;

EID: 0033052746     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199903000-00002     Document Type: Article

References (51)

1. Fidler IJ, Baleh CM. The biology of eaneer metastasis and implications for therapy. Citrr Proh Sura 1987;24:137-209.
2. Holmgren L, O’Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1995;1:149-53.
3. Haskell CM. Principles of cancer chemotherapy. In: Haskell CM, ed. Cancer treatment. Philadelphia: WB Saunders. 1995:31-57.
4. Fields KK, Elfenbein GJ, Perkins JB, Moscinski LC. High dose versus standard dose chemotherapy for the treatment of breast cancer. A review of current concepts. Ann NY Acad Sci 1995:770: 288-304.
5. Sulitzeanu D. Immunosuppressive factors in human cancer. In: Advances in cancer research. San Diego: Academic Press. 1993:60 247-67.
6. Quan WDY, Mitchell MS. Principles of biologic therapy. In: Haskell CM. ed. Cancer treatment. Philadelphia: WB Saunders, 1995:57-69.
7. Ben-Efraim S. Cancer immunotherapy: hopes and pitfalls. A review. Anticancer Res 1996; 16:3235-40.
8. Burstein Y, Buchner V, Pecht M, Trainin N. THF-γ2: purification and amino acid sequence of an immunoregulatory peptide from calf thymus. Biochemistry 1988;27:4066-71.
9. Kook AI, Yakir Y, Trainin N. Isolation and partial chemical characterization of THF, a thymus hormone involved in immune maturation of lymphoid cells. Cell Immunol 1975;19:151-7.
10. Katorza E, Pecht M, Apte RN, et al. Restoration of immunological responses by THF. a thymic hormone, in mice infected with murine cytomegalovirus (MCMV). Clin Exp Immunol 1987:70:268-75.
11. Ben-Hur H. Pecht M, Netzer L, et al. Immune modulation exerted by thymic humoral factor (THF-γ2). on T-cell subsets and IL-2 production of umbilical cord blood lymphocytes. Immunopharmacol lmmunotoxicol 1990;12:123-33.
12. Pecht M, Lourie S, Burstein Y, Zipori D, Trainin N. Potentiation of myeloid colony formation in bone marrow of intact and neonatallv thymectomized mice by the thymic hormone THF-γ2. Exp Hematol 1993;21:277-82.
13. Barak Y, Hahn T, Pecht M, et al. Thymic humoral factor-γ2, an immunoregulatory peptide, enhances human hematopoietic progenitor cell growth. Exp Hematol 1992:20:173-7.
14. Trainili N, Handzel ZT, Pecht M. Biological and clinical properties of THF. Thymus 1995:7:137-50.
15. Handzel ZT, Burstein Y, Buchner V, Pecht M, Trainin N. Immunomodulation of T-cel 1 deficiency in humans by thymic humoral factor: from the crude extract to synthetic THF-γ2. J Biol Response Mod 1990:9:269-78.
16. Trainin N. Prospects of AIDS therapy by thymic humoral factor, a thymic hormone. Nat Immuri Cell Growth Regni 1990:9:155-9.
17. Ophir R, Pecht M, Halperin D, et al. THF-γ2. a thymic hormone, increases immunocompetence and survival in 5-fluorouracil treated mice bearing MOPC-315 plasmacytoma. Cancer Immunol Immunother 1989:30:119-25.
18. Ophir R, Pecht M, Rashid G, et al. A synthetic thymic hormone, THF-γ2. repairs immunodeficiency of mice cured from plasmacytoma by melphalan. Int. J Cancer 1990:45:1190-1.
19. Ophir R, Pecht M, Relyveld FH, Burstein Y, Ben-Efraim S, Trainin N. THF-γ2, a synthetic thymic hormone, increases effectiveness of combined chemotherapy and immunotherapy against RPC-5 murine plasmacytoma. Int. J Immunopharmacol 1990:19: 751-4.
20. Ophir R, Pecht M, Burstein Y, Harshemesh H, Ben-Efraim S, Trainin N. Therapeutic effectiveness against MOPC-315 plasmacytoma of low or high doses of the synthetic thymic hormone THF-γ2 in combination with an immunomodulating or a nonimmunomodulating drug. Int J Cancer 1991:48:96-100.
21. Ophir R, Pecht M, Keisari Y. et al. Thymic humoral factor-γ2 (THF-γ2) immunotherapy reduces the metastatic load and restores immunocompetence in 3LL tumor-bearing mice receiving anticancer chemotherapv. Immunopharmacol Immunotoxicol 1996:18: 209-36.
22. Rashid G, Ophir R. Pecht M, et al. Inhibition of murine Lewis lung carcinoma by combined chemotherapy and intranasal THF-γ2 immunotherapy. J Immunother 1996:19:324-33.
23. Balch CM, Houghton AN, Peters LJ. Cutaneous melanoma. In: DeVita VT, Heilman S. Rosenberg SA. eds. Cancer-principles and practice of oncology. Philadelphia: JB Lippincott, 1993:1612-61
24. Kim YS, Slomsky R, Cohen EP. Immunity to melanoma in mice immunized w ith transfected allogeneic mouse fibroblasts expressing melanoma-associated antigens. Cancer Immunol Immunother 1991:34:163-8.
25. Feldman M, Eisenbach L. MHC class I genes controlling the metastatic phenotype of tumor cells. Semin Cancer Biol 1991:2:337-46.
26. Porgador A, Brenner B, Vadai E, Feldman M, Eisenbach L. Immunization by gamma-IFN treated B 16-F10.9 melanoma cells protects against metastatic spread of the parental tumor, Int J Cancer (Suppl) 1991; 6:54-60.
27. Katz A, Shulman LM, Porgador A, Revel M, Feldman M, Eisenbach L. Abrogation of B16 melanoma metastases by long-term low-dose interleukin-6 therapy. J Immunother 1993:13:98-109.
28. Plaskin D, Gelber C, Feldman M, Eisenbach L. Reversal of the metastatic phenotype in Lewis lung carcinoma cells after transfection with syngeneic H-2Kb gene. Proc Natl Acad Sci USA 1988: 85:4463-7.
29. Cochran AJ, Morton DL, Glapsy JA, Economou JS. Melanoma and skin cancer. In: Haskell CM, ed. Cancer treatment. Philadelphia: WB Saunders. 1995:810-24.
30. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983:65:55-63.
31. Young LS. Infection in cancer patients. In: Haskell CM, ed. Cancer treatment. Philadelphia: WB Saunders. 1995:206-16.
32. Atzpodien J, Lopez-Hanninen E, Kirchner H, et al. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-a after intra venous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin. carmustine and tamoxifen. EurJ Cancer 1995:31A:876-81.
33. Marcovitch S, Keisari Y. The synergistic tumoricidal activity of anticancer drugs and oxidative burst-triggered macrophages. Cancer Immunol Immunother 1985:20:205-8.
34. Stein-Streilein J, Toews GS. Leukocytes in the lung. In: Massaro D, ed. Lung cell biology. New York-Basel: Marcel Dekker, 1989: 441-85.
35. Porgador A, Feldman M, Eisenbach L. H-2Kb transfection of B16 melanoma cells results in reduced tumorigenidty and metastatic competence. J Immunogenet 1989:16:291-303.
36. Porgador A, Tzehoval E, Vadai E, Feldman M, Eisenbach L. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases. Cancer Res 1995:55: 4941-9.
37. Feldman M. Foundations in cancer research. From Aristotle, through Spcmann. to tumor immunology: a personal experience. Adi Cancer Res 1995:66:41-70.
38. Trainin N, Pecht M, Burstein Y. Thymic humoral factor THF-γ2: an immunoregulatory octapeptide. In: Frensdorff A, ed. Frontiers in cancer research. Tel Aviv: Tcl-Aviv University/Ramot Publishing, 1994:263-81.
39. Goso C, Frasca D, Doria G. Effect of synthetic thymic humoral factor (THF-γ2) on T cell activities in immunodeficient aging mice. Clin Exp Immunol 1992:87:346-51.
40. Rotter V, Globerson A, Nakamura I, Trainin N. Studies on characterization of the lymphoid target cell for activity of a thymus humoral factor. J Exp Med 1973:138:130-42.
41. Daniels HM, O’Toole A, Hussein MJ, Corridori S, Alexander GJM, Williams R. THF-γ2 stimulates cytokine release by peripheral blood mononuclear cells of patients w ith chronic hepatitis B virus infection. J Hepatol 1994:20:370-5.
42. Trainin N, Burstein Y, Ben-Efraim S, Goebel FD, Handzel ZT. The use of THF-γ2, a thymic hormone, for immunomodulation in cancer and AIDS. In: Lapis K. Ekhardt S. eds. Novel approaches in cancer therapy. Budapest: Lectures and symposia of the 14th International Cancer Congress. 1987:253-66.
43. Farhat BA, Marinos G, Daniels HM, Naoumov NV, Williams R. Evaluation of efficacy and safety of thymus humoral factor-gamma 2 in the management of chronic hepatitis B. J Hepatol 1995:23: 21-7.
44. Mastino A, Favalli C, Grelli S, Garaci E. Interaction between thymic hormones and other immunomodulatory agents. Ann 1st Super Sanita 1991:27:51-6.
45. Lopez M, Carpano S. Cavaliere R, et al. Biochemistry with thymosin oil, interleukin-2 and dacarbazine in patients with metastatic melanoma: clinical and immunological effects. Ann Oncol 1994: 5:741-6.
46. Dardenne M, Bach JF. Thymic hormone in the treatment of cancer. In: Mitchell MS. ed. Immunity to cancer 11. Progr Clin lliol Res 1987:288:363-82.
47. Ernst E. Thymus therapy for cancer? A criteria-based. systematic review. Eur J Cancer 1997:33:531-5.
48. O’Brein CJ, Nouri-Aria KT. Hegarty J, et al. In vitro effect of TP-1 (a calf thymic extract) on suppressor T-cell function of patients with autoimmune chronic active hepatitis. Int J Immunopharmacol 1988:10:651-6.
49. Lin CY, Low TL. A comparative study on the immunological effects of bovine and porcine thymic extracts: induction of lymphoproliferative response and enhancement of interleukin-2, gamma interferon and tumor necrotic factor production in vitro on cord blood lymphocytes. Immunopharmacology 1989:18:1-10.
50. Colarian J, Sethi A, Merchant A, Parikh N, Mutchnik M. Thymosin alpha-1 enhancement of human lymphocyte proliferation is not mediated by prostaglandin E2. Thymus 1990:15:241-7.
51. Leichtling KD, Serrata SA, Sztein MB. Thymosin alpha-1 modulates the expression of high affinity interleukin-2 receptors on normal human lymphocytes. Int J Immunopharmacol 1990:12:19-29.